Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel
NCT07537660 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2026-04-17
Summary
The goal of this clinical trial is to learn if auricular point stimulation plus dexamethasone works to effectively prevent or suppress nausea and vomiting caused by gemcitabine combined with paclitaxel protein-bound in pancreatic cancer treatment.
It will also learn about the safety and influence on gastrointestinal function of auricular point stimulation plus dexamethasone. The main questions it aims to answer are:
Can auricular point stimulation plus dexamethasone effectively prevent or suppress nausea and vomiting induced by the gemcitabine plus paclitaxel protein-bound regimen? Can auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions caused by excessive use of antiemetic drugs?
Participants will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy. Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct.
Conditions
- Nausea and Vomiting Caused by Chemotherapy
Interventions
- OTHER
-
Auricular point stimulation plus dexamethasone
On the day of chemotherapy (Day 1): Within half an hour before chemotherapy, administer auricular acupressure on one ear (stimulating the stomach, cardia, and brainstem acupoints for 5 minutes each) along with an intravenous push of 5 mg dexamethasone. From the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5): Stimulate each acupoint once in the morning, noon, and evening, for 5 minutes each time. If nausea or vomiting occurs, immediately apply additional stimulation for 5 minutes as a temporary measure. Oral antiemetics should be prepared and may be used temporarily if nausea and vomiting are significant and the patient feels the need.
Sponsors & Collaborators
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-25
- Primary Completion
- 2026-11-30
- Completion
- 2026-11-30
Countries
- China
Study Locations
More Related Trials
-
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
NCT00952341 ·Status: COMPLETED ·Phase: PHASE3
-
Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting
NCT07246070 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
NCT02364804 ·Status: COMPLETED
-
Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
NCT07130617 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
NCT01857232 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
NCT00104403 ·Status: COMPLETED ·Phase: PHASE2
-
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
NCT06200168 ·Status: RECRUITING ·Phase: PHASE3
-
Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting
NCT05143554 ·Status: TERMINATED ·Phase: NA
-
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
NCT02445872 ·Status: UNKNOWN ·Phase: PHASE2
-
Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients
NCT02403037 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851 ·Status: RECRUITING ·Phase: PHASE2
-
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
NCT00869310 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
NCT03668639 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
NCT07081256 ·Status: COMPLETED ·Phase: PHASE3
-
NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens
NCT06331520 ·Status: COMPLETED ·Phase: PHASE3
-
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
NCT05564286 ·Status: COMPLETED ·Phase: PHASE3
-
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
NCT00343863 ·Status: COMPLETED ·Phase: NA
-
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
NCT02484911 ·Status: COMPLETED ·Phase: PHASE3
-
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
NCT01275664 ·Status: TERMINATED ·Phase: NA
-
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
NCT00475085 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
NCT01909856 ·Status: COMPLETED ·Phase: PHASE2
-
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
NCT01736917 ·Status: COMPLETED ·Phase: PHASE2
-
Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin
NCT04201769 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
NCT03403712 ·Status: COMPLETED ·Phase: PHASE3
-
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
NCT01370408 ·Status: COMPLETED ·Phase: PHASE2